EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay

Kajsa Björkman iD, Harri Mustonen, Tuomas Kaprio, Caj Haglund, Camilla Böckelman

Tumor Biology · 2019-07 · 41 (7)

DOI: 10.1177/1010428319860728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tumor Biology, online erschienen am 01.07.2019. Verfasst von Kajsa Björkman und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1 Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: helsingin yliopisto, Finnish Cancer Foundation, Competitive State Research Financing of the Expert Responsibility of Helsinki University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers remains necessary. We analyzed preoperative serum samples from 148 colon cancer patients surgically treated at Helsinki University Hospital from 1998 through 2002 using a multiplex proximity extension assay (Oncology II panel, Olink Bioscience, Uppsala, Sweden), a panel constituting 92 immunological and oncological markers. We performed univariate and multivariate analyses on these patients and calculated the disease-specific survival among patients using the log-rank test for Kaplan–Meier estimates. In the univariate survival analysis of 92 biomarkers, 26 resulted in p < 0.1. Among these, eight biomarkers emerged as statistically significant (p < 0.05). Patients with low levels of kallikrein 13 had a poor prognosis. Moreover, patients with high levels of amphiregulin, carcinoembryonic antigen-related adhesion molecule 5, interleukin 6, mucin 16, syndecan 1, transforming growth factor alpha, and vimentin also had a poor prognosis. In the multivariate analysis, kallikrein 13 and mucin 16 emerged as independent prognostic markers. The role of kallikrein 13, a member of the serine protease kallikrein biomarker family, in tumorigenesis remains unclear. Mucin 16 is also known as carbohydrate antigen 125, a well-known ovarian cancer biomarker. Patients with low levels of kallikrein 13 (hazard ratio: 0.36; 95% confidence interval: 0.14–0.92; p = 0.033) and high levels of mucin 16 (hazard ratio: 3.15; 95% confidence interval: 1.68–5.93; p < 0.005) had a poor prognosis. Mucin 16 and kallikrein 13 represent independent prognostic markers for colon cancer. Furthermore, the clinical utility of mucin 16 and kallikrein 13 serum tests warrants additional investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedBiomarkers, TumorCA-125 AntigenColonic NeoplasmsFemaleHumansImmunoassayKallikreinsKaplan-Meier EstimateMaleMembrane ProteinsMiddle AgedMultivariate AnalysisPrognosisSurvival Analysis

Stichwörter der Autor:innen

Colon cancerKLK13MUC-16prognosisproximity extension assay

Substanzen

Biomarkers, TumorCA-125 AntigenMUC16 protein, humanMembrane ProteinsKLK13 protein, humanKallikreins

Autor:innen und Institutionen

  • 1 Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland.
  • 2 Meilahti Hospital, Helsinki, Finland.
  • 3 Department of Surgery, University of Helsinki, Helsinki, Finland.
  • 4 Helsinki University Hospital, Helsinki, Finland.

ORCID-Profile: Kajsa Björkman

Förderung

  • helsingin yliopisto
  • Finnish Cancer Foundation
  • Competitive State Research Financing of the Expert Responsibility of Helsinki University Hospital
  • Finska Lkaresllskapet
  • Sigrid Jusliuksen Sti

Zitieren

APA

Björkman, K., Mustonen, H., Kaprio, T., Haglund, C., & Böckelman, C. (2019). Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay. Tumor Biology, 41(7). https://doi.org/10.1177/1010428319860728

Vancouver

Björkman K, Mustonen H, Kaprio T, Haglund C, Böckelman C. Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay. Tumor Biology. 2019;41(7). doi:10.1177/1010428319860728

BibTeX
@article{Bjrkman2019,
  author = {Björkman, Kajsa and Mustonen, Harri and Kaprio, Tuomas and Haglund, Caj and Böckelman, Camilla},
  title = {Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay},
  journal = {Tumor Biology},
  year = {2019},
  volume = {41},
  number = {7},
  doi = {10.1177/1010428319860728}
}
Kostenlos starten →